Table 2.
Short‐term neonatal outcomes of children participating in the follow‐up study 9
| Nifedipine (n = 115) | Atosiban (n = 110) | P | |
|---|---|---|---|
| Gestational age at birth | 33+0 (30+3–35+2) | 31+6 (29+4–34+5) | 0.16 |
| Gestational age at birth | |||
| <28 weeks | 10 (8.7%) | 13 (11%) | 0.44 |
| 28–32 weeks | 38 (33%) | 42 (38%) | |
| >32 weeks | 67 (58%) | 55 (50%) | |
| Adverse perinatal composite outcome a | 13 (11%) | 15 (14%) | 0.60 |
| Bronchopulmonary dysplasia | 4 (3.5%) | 7 (6.4%) | 0.33 |
| Culture‐proven sepsis | 11 (9.6%) | 8 (7.3%) | 0.54 |
| Intraventricular haemorrhage (grade ≥3) | 2 (1.7%) | 0 (0.0%) | — |
| Periventricular leukomalacia (grade ≥2) | 0 (0.0%) | 1 (0.9%) | — |
| Necrotising enterocolitis (stage ≥2) | 4 (3.5%) | 1 (0.9%) | 0.22 |
| NICU admission b | 66 (57%) | 71 (65%) | 0.26 |
| Length (days) d | 14.5 (6.0–38.5) | 18.0 (7.0–43.5) | 0.75 |
| Intubation c | 11 (9.6%) | 24 (23%) | 0.017 |
| Length (days) d | 6.0 (2.0–13.5) | 2.5 (1.0–5.2) | 0.082 |
| Any hospital admission | 103 (90%) | 102 (93%) | 0.41 |
| Days in hospital | 32.0 (18.5–54.0) | 34.0 (21.0–62.0) | 0.85 |
| Apnoea | 8 (7.0%) | 13 (12%) | 0.12 |
| Asphyxia | 0 (0.0%) | 1 (0.9%) | — |
| Proven meningitis | 2 (1.7%) | 0 (0.0%) | — |
| Birthweight (g) | 1920 (1553–2629) | 1805 (1368–2419) | 0.15 |
Outcome data are n (%) or median (IQR). Data are reported until the corrected age of 3 months.
a
Composed of perinatal in‐hospital mortality and the following perinatal morbidities: bronchopulmonary dysplasia, culture‐proven sepsis, intraventricular haemorrhage higher than grade 2, periventricular leukomalacia higher than grade 1 and necrotising enterocolitis higher than Bell’s stage 1.
b
Nifedipine, n = 115; atosiban, n = 109.
c
Nifedipine, n = 114; atosiban, n = 106.
d
Only reported for neonates who were admitted to the neonatal intensive care unit (NICU) or who underwent intubation.